The chronic kidney disease drugs market comprises prescription medications used to slow down the progression of chronic kidney disease and treat complications associated with reduced kidney function. Drugs associated with the market include ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta-blockers, erythropoiesis-stimulating agents, and phosphate binders. Chronic kidney disease impacts nearly 15% of the global population, and its management has become increasingly important. The drugs aid in controlling high blood pressure, anemia, and high phosphate levels in chronic kidney patients to delay or prevent the need for renal replacement therapy like dialysis and transplantation. The Global chronic kidney disease drugs market is estimated to be valued at US$15,086.22 Mn in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the chronic kidney disease drugs are Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson and Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd. The chronic kidney disease market offers ample opportunities for companies involved in developing innovative combination drugs for improved treatment. Development of novel drug delivery systems is also opening new doors in this domain. Increased focus on global health initiatives to curb kidney disease prevalence worldwide will aid market expansion across regions. Market Drivers The Global Chronic Kidney Disease Drugs Market Demand will majorly be driven by the rising epidemic of kidney diseases worldwide due to lifestyle diseases like diabetes and hypertension. Over 10% of the global population is affected by chronic kidney disease currently, offering a large patient pool for pharmaceutical companies. Increasing approvals of new medications and combinations hold potential to boost market revenues over the forecast period.
PEST Analysis Political: Chronic kidney disease drugs are strictly regulated by various government bodies. Any changes in regulations can impact the overall market. Economic:Growing per capita healthcare expenditure in developing countries and increasing uptake of health insurances are driving demand for chronic kidney disease drugs. Social: Rising awareness regarding kidney diseases and availability of various treatment options is propelling the chronic kidney disease drugs market. Additionally, support from patient advocacy groups and associations also supplements market growth. Technological: Advancements in areas of drug delivery systems, biologics, and biomarkers are expected to introduce more effective and personalized treatment options for chronic kidney disease patients in future. Geographical Regions with High Market Concentration North America holds the largest share in chronic kidney disease drugs market owing to factors such as increasing prevalence of diseases, presence of well-established healthcare infrastructure, and favorable reimbursement policies. The U.S. accounts for majority of the region's market share. Europe is the second largest regional market supported by growing government funding for research activities and development of innovative treatment approaches. Countries such as Germany, U.K, and France are major revenue contributors. Fastest Growing Regional Market Asia Pacific region is identified as the most lucrative and fastest growing market for chronic kidney disease drugs. Rapidly improving healthcare facilities, rising healthcare expenditure, growing medical tourism, increasing acceptance of novel therapies, and large patient pool are some key factors fueling the Asia Pacific market. China and India are anticipated to be highly profitable markets over the coming years.
Get more insights on Chronic Kidney Disease Drugs Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Chronic kidney disease (CKD) entails a sluggish lack of functioning of kidneys.
The ordinary characteristic of kidneys is to filter and excrete wastes, and extra fluids from the blood are excreted via urine.
However, whilst a character is tormented by continual kidney sickness, kidneys can not carry out their herbal characteristic, and wastes, fluids, and electrolytes building up withinside the frame in extra amounts.
Signs and signs and symptoms of continual kidney sickness aren't obvious till kidney characteristic turns into substantially impaired.
The supportive remedy of continual kidney sickness consists of delaying the sickness development and kidney harm.
Diseases and situations together with kind 1 or kind 2 diabetes, excessive blood strain, polycystic kidney sickness, and recurrent kidney contamination end in continual kidney sickness.
